Using tranexamic acid to reduce blood loss in hip fracture surgeries
Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?
This study is testing if giving tranexamic acid before and after hip fracture surgery can help reduce blood loss for adults undergoing this procedure.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 170 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ascension Health Industry-sponsored |
| Locations | 1 site (Grand Blanc, Michigan) |
| Trial ID | NCT05047133 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of tranexamic acid (TXA) in reducing postoperative blood loss in adults with hip fractures undergoing surgical fixation. The study is conducted at a Level II trauma center and involves administering TXA intravenously before incision and at wound closure. By assessing blood loss in both intracapsular and extracapsular hip fractures, the trial aims to establish a standard dosing pattern that could improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who present with an acute hip fracture requiring surgical intervention.
Not a fit: Patients with coagulopathies, recent thromboembolic events, or other specified exclusions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the need for blood transfusions in hip fracture patients.
How similar studies have performed: Previous studies have shown that TXA effectively reduces blood loss in similar surgical contexts, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation Exclusion Criteria: 1. Polytrauma patients 2. Previous operation on the ipsilateral hip 3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.) 4. Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI) 5. History of seizure disorder 6. Patients on birth control 7. Pregnant Women 8. Prisoners 9. Active thromboembolic disease (DVT/PE, MI, Stroke)
Where this trial is running
Grand Blanc, Michigan
- Ascension Genesys Hospital — Grand Blanc, Michigan, United States (Recruiting)
Study contacts
- Study coordinator: Jacob Hinkley, DO, MS
- Email: jacob.hinkley2@ascension.org
- Phone: 810-606-5669
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.